ecrin-mdr-crcClinical2022IPD Sharing (as of March 2023): NoLymphoma, Large B-Cell, DiffuseLymphoma, T-CellCarcinomaTriple Negative Breast NeoplasmsCarcinoma, Non-Small-Cell LungHodgkin DiseaseLymphoma, T-Cell, PeripheralColorectal CancerNon Small Cell Lung CancerTriple Negative Breast CancerHormone Receptor Positive Breast CarcinomaBreast NeoplasmsCutaneous Squamous Cell CarcinomaLymphoma, B-CellSmall Bowel CancerHodgkin LymphomaSquamous Cell Carcinoma of Head and NeckEsophageal NeoplasmsColorectal NeoplasmsSolid TumorDiffuse Large B Cell LymphomaBurkitt LymphomaLymphomaDiffuse large B-cell lymphomaCarcinoma, Squamous CellHead and Neck Squamous Cell CarcinomaT-cell LymphomaEsophageal CancerLymphoma, Large B-cell, DiffuseCarcinomaTriple Negative Breast NeoplasmsHodgkin DiseaseColorectal CancerNon Small Cell Lung CancerTriple Negative Breast CancerHormone Receptor Positive Breast CarcinomaBreast NeoplasmsCutaneous Squamous Cell CarcinomaSmall Bowel CancerHodgkin LymphomaEsophageal NeoplasmsColorectal NeoplasmsCarcinoma, Non-small-cell LungHead And Neck Squamous Cell CarcinomaLymphoma, T-cellLymphoma, T-cell, PeripheralSolid TumorDiffuse Large B Cell LymphomaBurkitt LymphomaDiffuse Large B-cell LymphomaLymphomaCarcinoma, Squamous CellSquamous Cell Carcinoma Of Head And NeckT-cell LymphomaEsophageal CancerLymphoma, B-cellInterventionalhttps://newmdr.ecrin.org/Study/2750284United States11CD161Hormone receptor positive breast cancerSmall bowel carcinomaECRIN MDRRecruitingfalseStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasThis is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-0092022-11-152750284NCT05565417